Correction to: Crit Care 24, 442 (2020)
https://doi.org/10.1186/s13054-020-03122-y
Anzeige
Following publication of the original article [1], the authors reported errors in Table 1 and Table 2.
The revised Table 1 and Table 2 are indicated hereafter.
Table 1
Patients demographic and clinical characteristics
All (n = 200) | Levosimendan (n = 53) | Control (n = 147) | p value | |
|---|---|---|---|---|
Clinical characteristics at ICU admission | ||||
Age (years) | 53 ± 13.5 | 53.9 ± 14.3 | 52.6 ± 13.3 | 0.575 |
Male | 129 (64.5) | 33 (62.3) | 96 (65.3) | 0.692 |
BMI (kg/m2) | 25.3 ± 5.4 | 25.3 ± 5.6 | 25.3 ± 5.3 | 0.975 |
SAPS-II | 52.2 ± 14.3 | 53.5 ± 10.8 | 51.7 ± 15.4 | 0.349 |
SOFA | 11.7 ± 2.1 | 11.5 ± 1.5 | 11.8 ± 2.2 | 0.459 |
Comorbidities | ||||
Hypertension | 62 (31) | 18 (34) | 44 (29.9) | 0.587 |
Diabetes | 36 (18) | 11 (20.8) | 25 (17) | 0.430 |
History of congestive heart failure | 101 (51) | 26 (50) | 75 (51.4) | 0.865 |
Coronary artery disease | 88 (44) | 27 (50.9) | 61 (41.5) | 0.235 |
Peripheral artery disease | 11 (5.5) | 4 (7.5) | 7 (4.8) | 0.446 |
History of stroke | 14 (7) | 5 (9.4) | 9 (6.1) | 0.418 |
Smoking | 71 (35.5) | 18 (34) | 53 (36.1) | 0.785 |
Dyslipidemia | 49 (24.5) | 14 (26.4) | 35 (23.8) | 0.705 |
Renal failure with dialysis | 15 (7.5) | 3 (5.6) | 12 (8.1) | 0.553 |
Indication for VA-ECMO | 0.068 | |||
Post-cardiotomy | 59 (29.5) | 18 (34) | 41 (27.9) | |
Acute myocardial infarction | 45 (22.5) | 17 (32.1) | 28 (19) | |
Graft dysfunction | 33 (16.5) | 3 (5.7) | 30 (20.4) | |
Dilated cardiomyopathy | 15 (7.5) | 5 (9.4) | 10 (6.8) | |
Intoxication | 14 (7) | 0 (0) | 14 (9) | |
Fulminant myocarditis | 13 (6.5) | 3 (5.7) | 10 (6.8) | |
Pulmonary embolism | 6 (3) | 2 (3.8) | 4 (2.7) | |
Septic cardiomyopathy | 6 (3) | 2 (3.8) | 4 (2.7) | |
Others | 9 (4.5) | 3 (5.6) | 6 (4) | |
Potential for myocardial recovery | 0.264 | |||
High | 39 (19.5) | 7 (13.2) | 32 (21.8) | |
Intermediate | 86 (43) | 22 (41.5) | 64 (43.5) | |
Low | 75 (37.5) | 24 (45.3) | 51 (34.7) | |
Hemodynamic parameters at admission | ||||
LVEF (%) | 19.6 ± 11.3 | 18 ± 11.1 | 20.2 ± 11.4 | 0.241 |
TAPSE < 12 (mm) | 45 (30.8) | 15 (34.8) | 30 (29.1) | 0.489 |
MAP (mmHg) | 69 ± 11 | 70 ± 11 | 69 ± 11 | 0.643 |
HR (beats/min) | 103 ± 24 | 108 ± 21 | 102 ± 25 | 0.145 |
CVP (mmHg) | 10.6 ± 5 | 10.8 ± 5.5 | 10.6 ± 4.9 | 0.798 |
ScvO2 (%) | 62 ± 11 | 60 ± 12 | 63 ± 11 | 0.065 |
VA-ECMO characteristics | ||||
VA-ECMO duration (days) | 7.6 ± 5 | 10.6 ± 4.8 | 6.5 ± 4.7 | < 0.001 |
Flow rate (L/min) | 3.5 ± 0.8 | 3.4 ± 0.8 | 3.5 ± 0.8 | 0.835 |
Rotation (round/min) | 4360 ± 1711 | 4480 ± 1724 | 4312 ± 1710 | 0.547 |
FiO2 (%) | 59 ± 12 | 58 ± 12 | 59 ± 13 | 0.977 |
Peripheral VA-ECMO canulation | 175 (87.5) | 48 (90.6) | 127 (86.4) | 0.496 |
IABP associated to VA-ECMO | 54 (27) | 16 (30.1) | 38 (25.8) | 0.542 |
Biological parameters | ||||
Hemoglobin level (g/dL) | 113 ± 25 | 114 ± 26 | 113 ± 24 | 0.717 |
International normalized ratio | 1.6 ± 0.6 | 1.5 ± 0.5 | 1.6 ± 0.6 | 0.338 |
Arterial blood pH | 7.26 ± ± 0.1 | 7.27 ± 0.1 | 7.26 ± 0.1 | 0.652 |
Lactate level (mmol/L) | 7.2 ± 5.1 | 6.4 ± 4.7 | 7.5 ± 5.3 | 0.178 |
Creatinine level (μmol/L) | 152 ± 78 | 150 ± 77 | 153 ± 79 | 0.843 |
Total bilirubin level (μmol/L) | 23 ± 17 | 22 ± 17 | 24 ± 17 | 0.457 |
ASAT (U/L) | 763 ± 1819 | 717 ± ± 1454 | 781 ± 1945 | 0.828 |
ALAT (U/L) | 390 ± 907 | 295 ± 610 | 426 ± 998 | 0.372 |
Catecholamines during ICU stay | ||||
Norepinephrine max dose (μg/kg/min) | 1.49 ± 1.05 | 1.56 ± 1.07 | 1.47 ± 1.04 | 0.586 |
Norepinephrine duration (days) | 10.9 ± 8.7 | 12.8 ± 7.2 | 10.2 ± 9.2 | 0.068 |
Dobutamine max dose (μg/kg/min) | 9.7 ± 4.6 | 10.4 ± 10.2 | 9.5 ± 4.3 | 0.309 |
Dobutamine duration (days) | 9.1 ± 7.9 | 10.3 ± 10.2 | 8.6 ± 6.6 | 0.203 |
Table 2
Balance of covariates before and after matching
Unmatched* | Matched | |||||
|---|---|---|---|---|---|---|
Levosimendan (n = 48) | Control (n = 128) | p | Levosimendan (n = 48) | Control (n = 78) | p | |
Variable (mean) | ||||||
Age (years) | 53.9 | 52.6 | 0.575 | 54.3 | 54.7 | 0.866 |
Male (%) | 62 | 65 | 0.692 | 0.62 | 0.65 | 0.785 |
Potential for recovery | 2.32 | 2.12 | 0.104 | 2.31 | 2.35 | 0.747 |
SAPS-II | 53.5 | 51.7 | 0.424 | 52.7 | 52.1 | 0.824 |
SOFA | 11.5 | 11.8 | 0.530 | 11.3 | 11.5 | 0.687 |
LVEF (%) | 18 | 20.2 | 0.241 | 18 | 17 | 0.690 |
VA-ECMO duration (days) | 10.6 | 6.5 | < 0.001 | 10.8 | 10.2 | 0.478 |
Serum lactate level (mmol/L) | 6.4 | 7.5 | 0.178 | 6.3 | 6.1 | 0.816 |
The original article [1] has been updated.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.